image: Dr. Bayewitch has more than 22 years of experience in the pharmaceutical industry, including in due diligence and in/out-licensing transactions, focusing on oncology, autoimmune diseases, and respiratory diseases. view more
Credit: Insilico Medicine
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy. Based on the West Coast, Dr. Bayewitch will work closely with Alex Zhavoronkov, PhD, founder and CEO, Feng Ren, PhD, Co-CEO and CSO, and Michelle Chen, PhD, Chief Business Officer. He is responsible for driving business development activities and developing attainable operation strategies to support Insilico's continued growth.
Dr. Bayewitch is an accomplished industry veteran with more than 22 years of experience in the pharmaceutical industry, including in due diligence and in/out-licensing transactions, focusing on oncology, autoimmune diseases, and respiratory diseases. Prior to Insilico Medicine, he worked for international mid- and large-size pharmaceutical companies including ITI Life Sciences, Teva Pharmaceuticals Inc., and EOC Pharma, and most recently served as Executive Director of International Business Development for Simcere Pharmaceutical Group, where he performed opportunity identification, analysis, and forecast resulting in multiple licensing deals.
“As we witness the rapid development of the pharmaceutical industry and the dramatic innovation of AI technology, Insilico sees increasing demand for internal staff as more pipelines are entering the clinical stage,” said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine. “In this promising and challenging year for Insilico, we look forward to accelerated growth supported by Dr. Bayewitch's combined expertise.”
Having graduated from University of California at Santa Barbara with a B.A. in Microbiology, Dr. Bayewitch continued his studies at Weizmann Institute of Science Rehovot. He subsequently worked as a post-doctoral research associate at Salk Institute, where he focused on myelin specific proteins.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS), and aging-related diseases.
For more information, visit www.insilico.com